Articles

Daratumumab plus Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a 4-Arm Phase 1b Study

ASH 2015 - Multiple Myeloma

Conference Correspondent

Ixazomib plus Lenalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM): Results of the Phase 3 Tourmaline-MM1 Study

ASH 2015 - Multiple Myeloma

Conference Correspondent

Carfilzomib plus Filanesib versus Carfilzomib in Patients with Advanced Multiple Myeloma

ASH 2015 - Multiple Myeloma

Conference Correspondent

Subgroup Analysis of the ENDEAVOR Study of Carfilzomib/Dexamethasone versus Bortezomib/Dexamethasone in Patients with Relapsed MM

ASH 2015 - Multiple Myeloma

Conference Correspondent

Subgroup Analysis Based on Cytogenetic Risk Status: Carfilzomib / Lenalidomide / Dexamethasone versus Lenalidomide / Dexamethasone (ASPIRE Study)

ASH 2015 - Multiple Myeloma

Conference Correspondent

Lenalidomide Maintenance in Patients with Relapsed DLBCL Who Cannot Be Treated with Consolidative Transplantation

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Addition of Obinutuzumab or Rituximab to Chlorambucil in Treatment-Naive Patients with CLL: Updated Survival Analysis from the CLL11 Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Impact of High-Risk Prognostic Parameters on Ibrutinib/Bendamustine/Rituximab versus Bendamustine/Rituximab Treatment Outcomes in Patients with Relapsed CLL/SLL: Results from the HELIOS Trial

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Health-Related Quality-of-Life Assessment of Obinutuzumab plus Bendamustine versus Bendamustine in Patients with Rituximab-Refractory Indolent NHL: Results of the GADOLIN Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Effect of Ibrutinib versus Temsirolimus Treatment on Lymphoma Symptoms in Patients with Previously Treated Mantle-Cell Lymphoma (MCL): Results of the RAY (MCL3001) Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Page 179 of 329